Daily Stock Analysis, BCLI, Brainstorm Cell Therapuetics Inc, priceseries

Brainstorm Cell Therapuetics Inc. Daily Stock Analysis
Stock Information
Open
3.94
Close
3.97
High
3.98
Low
3.93
Previous Close
3.92
Daily Price Gain
0.05
YTD High
4.50
YTD High Date
Jul 12, 2019
YTD Low
3.31
YTD Low Date
Jan 2, 2019
YTD Price Change
0.51
YTD Gain
14.74%
52 Week High
4.50
52 Week High Date
Jul 12, 2019
52 Week Low
2.92
52 Week Low Date
Dec 10, 2018
52 Week Price Change
0.45
52 Week Gain
12.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
2.84
Feb 24. 2017
3.60
17 Trading Days
26.69%
Link
LONG
May 11. 2018
3.64
Jun 7. 2018
4.66
18 Trading Days
27.90%
Link
LONG
Jun 17. 2019
3.69
Jul 16. 2019
4.17
20 Trading Days
13.09%
Link
Company Information
Stock Symbol
BCLI
Exchange
NasdaqCM
Company URL
http://www.brainstorm-cell.com
Company Phone
201-488-0460
CEO
Chaim Lebovits
Headquarters
New Jersey
Business Address
3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK, NJ 07601
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001137883
About

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops innovative adult stem cell therapeutic products. It currently focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in Hackensack, NJ.

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.